A Closer Look at 6 Analyst Recommendations For SI-BONE
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse opinions on SI-BONE (NASDAQ:SIBN) with 6 recent ratings ranging from bullish to bearish. The average 12-month price target is $25.67, reflecting a slight increase from the previous $25.33. SI-BONE, a medical device company, shows a positive revenue trend with a growth rate of 21.61% as of December 31, 2023, but struggles with a net margin of -28.26% and an ROA of -4.76%. The company's financial health is indicated by an exceptional ROE of -6.4% and a low debt-to-equity ratio of 0.23.
May 07, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SI-BONE has received diverse analyst ratings with a slight increase in the average price target to $25.67, indicating a positive outlook. The company's strong revenue growth contrasts with its profitability challenges.
The increase in the average price target suggests a positive sentiment among analysts, which could lead to short-term price appreciation. However, the company's profitability issues, as indicated by its negative net margin and ROA, may temper investor enthusiasm. The strong revenue growth and exceptional ROE highlight the company's potential and operational efficiency, which could bolster investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100